pharmaphorum

JANUARY 28, 2021

In 2020, we saw seven of the 20 biosimilars currently available in the US launch. The United States biosimilar market experienced a significant increase in competition in 2020. As a result of the regulatory changes that occurred in March 2020, the first potential insulin biosimilar is on the horizon. million patients.

Biosimilars 119

Biosimilars Insurance Coverage and Processing Drug Pricing Diabetes 119

Putting Patients First Blog

JULY 2, 2024

General Comments The NHC appreciates CMS’ commitment to actively engaging with stakeholders, including patients, consumer advocates, and health experts, in implementing the Medicare Drug Price Negotiation Program (DPNP). The NHC provides the following comments to CMS to improve on the steps it has already taken to date.

Drug Pricing 52

Drug Pricing Insurance Coverage and Processing Labelling HIPAA 52

Putting Patients First Blog

JANUARY 27, 2025

Coverage of Anti-Obesity Medications (AOMs) The NHC applauds CMS for aligning with the medical community and proposing to recognize obesity as a chronic disease and allow Medicare Part D coverage for AOMs. Below, we provide detailed comments and recommendations on key provisions of the proposed rule.

Insurance Coverage and Processing 40

Insurance Coverage and Processing Biosimilars Communication Department of Veterans Affairs 40

Proxsys Rx

AUGUST 16, 2023

“Don’t believe drug companies: 340B is a program worth saving” On Tuesday, August 8, The Hill published a guest editorial (title above) by John Hassell — national director of advocacy at the AIDS Healthcare Foundation (AHF). First, start with presenting drug company-funded research as if it is non-biased.

Insurance Coverage and Processing 52

Insurance Coverage and Processing Hospitals Drug Pricing Pharmaceutical Companies 52